{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:44:32Z","timestamp":1793774672545,"version":"4.6.1"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Uninterrupted targeted therapy until disease progression or intolerable toxic effects is currently the routine therapy for advanced non\u2212small cell lung cancer (NSCLC) involving driver gene variations. However, drug resistance is inevitable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the clinical feasibility of adaptive de-escalation tyrosine kinase inhibitor (TKI) treatment guided by circulating tumor DNA (ctDNA) for achieving complete remission after local consolidative therapy (LCT) in patients with advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This prospective nonrandomized controlled trial was conducted at a single center from June 3, 2020, to July 19, 2022, and included 60 patients with advanced NSCLC with driver variations without radiologically detectable disease after TKI and LCT. The median (range) follow-up time was 19.2 (3.8-29.7) months. Data analysis was conducted from December 15, 2022, to May 10, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Cessation of TKI treatment and follow-up every 3 months. Treatment was restarted in patients with progressive disease (defined by the Response Evaluation Criteria in Solid Tumors 1.1 criteria), detectable ctDNA, or elevated carcinoembryonic antigen (CEA) levels, whichever manifested first, and treatment ceased if all indicators were negative during follow-up surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Progression-free survival (PFS). Secondary end points were objective response rate, time to next treatment, and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the total study sample of 60 participants (median [range] age, 55 [21-75] years; 33 [55%] were female), the median PFS was 18.4 (95% CI, 12.6-24.2) months and the median (range) total treatment break duration was 9.1 (1.5-28.1) months. Fourteen patients (group A) remained in TKI cessation with a median (range) treatment break duration of 20.3 (6.8-28.1) months; 31 patients (group B) received retreatment owing to detectable ctDNA and\/or CEA and had a median PFS of 20.2 (95% CI, 12.9-27.4) months with a median (range) total treatment break duration of 8.8 (1.5-20.6) months; and 15 patients (group C) who underwent retreatment with TKIs due to progressive disease had a median PFS of 5.5 (95% CI, 1.5-7.2) months. For all participants, the TKI retreatment response rate was 96%, the median time to next treatment was 29.3 (95% CI, 25.3-35.2) months, and the data for overall survival were immature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this nonrandomized controlled trial suggest that this adaptive de-escalation TKI strategy for patients with NSCLC is feasible in those with no lesions after LCT and a negative ctDNA test result. This might provide a de-escalation treatment strategy guided by ctDNA for the subset of patients with advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"NCT03046316\">NCT03046316<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1779","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T11:02:51Z","timestamp":1718276571000},"page":"932","source":"Crossref","is-referenced-by-count":84,"title":["Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non\u2212Small Cell Lung Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Song","family":"Dong","sequence":"first","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingfa","family":"Yan","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Si","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang Maggie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China"},{"name":"Chinese Thoracic Oncology Group, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Gong","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri-Qiang","family":"Liao","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Tao","family":"Lin","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E-E.","family":"Ke","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelong","family":"Xu","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Xia","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Na","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yi","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"},{"name":"Chinese Thoracic Oncology Group, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ning","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"},{"name":"Chinese Thoracic Oncology Group, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"coi240019r1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"coi240019r2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"coi240019r3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"coi240019r4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"coi240019r5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"coi240019r6","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi240019r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial.","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"coi240019r8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer.","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"coi240019r9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"coi240019r10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation-how, and when? data from melanoma as a paradigm.","volume":"17","author":"Robert","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"coi240019r11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","article-title":"Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.","volume":"11","author":"Le Cesne","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi240019r12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial.","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi240019r13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.","volume":"18","author":"Dr\u00e9no","year":"2017","journal-title":"Lancet Oncol"},{"issue":"75","key":"coi240019r14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"coi240019r15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi240019r16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial.","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"key":"coi240019r17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"issue":"16","key":"coi240019r18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","article-title":"A phase ii study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma.","volume":"35","author":"Ornstein","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi240019r19","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","article-title":"Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.","volume":"26","author":"Algazi","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"coi240019r20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"coi240019r21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor dna dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer.","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"issue":"7","key":"coi240019r22","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer.","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"coi240019r23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jtho.2023.05.027","article-title":"Longitudinal monitoring of circulating tumor dna from plasma in patients with curative resected stages I to IIIA EGFR-mutant non-small cell lung cancer.","volume":"18","author":"Jung","year":"2023","journal-title":"J Thorac Oncol"},{"key":"coi240019r24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2019.06.021","article-title":"The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a prospective study.","volume":"134","author":"Ding","year":"2019","journal-title":"Lung Cancer"},{"issue":"9","key":"coi240019r25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"12","key":"coi240019r26","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade.","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"coi240019r27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cllc.2021.10.001","article-title":"Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer.","volume":"23","author":"Page","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"coi240019r29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer.","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"27","key":"coi240019r30","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi240019r31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","article-title":"Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.","volume":"9","author":"Shi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"27","key":"coi240019r32","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"coi240019r33","doi-asserted-by":"publisher","first-page":"S1553","DOI":"10.1016\/j.annonc.2022.10.333","article-title":"LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: a multicentre, open-label, randomized phase III study.","volume":"33","author":"Lu","year":"2022","journal-title":"Ann Oncol"},{"key":"coi240019r34","doi-asserted-by":"publisher","first-page":"S1560","DOI":"10.1016\/j.annonc.2022.10.349","article-title":"LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829).","volume":"33","author":"Cho","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"coi240019r35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs.","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi240019r36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cllc.2018.09.015","article-title":"Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC).","volume":"20","author":"Elamin","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"coi240019r37","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"coi240019r38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00280-015-2942-1","article-title":"Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.","volume":"77","author":"Koo","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"coi240019r39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"coi240019r40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jtho.2022.10.021","article-title":"Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia.","volume":"18","author":"Mitsudomi","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"22","key":"coi240019r41","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer.","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"coi240019r42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.","volume":"76","author":"Grunnet","year":"2012","journal-title":"Lung Cancer"},{"issue":"6","key":"coi240019r43","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.2001.19.6.1865","article-title":"2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.","volume":"19","author":"Bast","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi240019r44","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12885-017-3474-3","article-title":"Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.","volume":"17","author":"Gao","year":"2017","journal-title":"BMC Cancer"},{"issue":"6378","key":"coi240019r45","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test.","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"coi240019r28","unstructured":"Guangdong Association of Clinical Trials. Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy (LOCAL). Accessed May 13, 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT03046316"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2820083\/jamaoncology_dong_2024_oi_240019_1720732612.63239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T11:03:41Z","timestamp":1721300621000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2820083"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1779","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}